Recent Articles from MarketBeat

MarketBeat is an American financial media company headquartered in Sioux Falls, South Dakota, founded in 2011 by Matthew Paulson as Analyst Ratings Network before rebranding in 2015. The company operates an online platform that delivers real-time financial data, market analysis, and news, aiming to empower individual investors with tools to make informed trading decisions.

The SK Hynix IPO and 2027’s AI Memory Squeezemarketbeat.com
SK Hynix's US debut raised $28.1 billion before shares fell, while Micron also dropped in sympathy, as memory makers face a persistent HBM supply crunch amid a maturing triopoly.
Via MarketBeat · July 13, 2026
Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debutsmarketbeat.com
Meta Platforms stock is rallying as its new Muse Spark 1.1 AI model shows improved intelligence scores and marks Meta's first push to monetize AI models via per-token pricing.
Via MarketBeat · July 13, 2026
Why Welltower's Growth Story Might Outrun Its Rich Valuationmarketbeat.com
Welltower's NOI and NFFO growth support its premium valuation, but housing data on senior aging-in-place trends and mortgage rate lock-in complicate its demographic growth thesis.
Via MarketBeat · July 13, 2026
TriCo Bancshares to Merge With First Hawaiian in $2B All-Stock Bank Dealmarketbeat.com
First Hawaiian and TriCo Bancshares (NASDAQ:TCBK) announced a definitive agreement to combine in an all-stock transaction that executives said would create a larger Pacific and West Coast banking franchise with approximately $34 billion in assets. On an investor call discussing the deal, First Hawa
Via MarketBeat · July 13, 2026
One Short- and One Long-Term ETF for Quantum Computing Bullsmarketbeat.com
As quantum stocks slump in 2025, ETFs like WisdomTree's WQTM and Defiance's QTUM offer diversified exposure, suiting long-term and short-term investors with differing risk and liquidity needs.
Via MarketBeat · July 13, 2026
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directionsmarketbeat.com
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Via MarketBeat · July 13, 2026
Q32 Bio’s Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Studymarketbeat.com
Q32 Bio (NASDAQ:QTTB) reported positive 36-week top-line results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata, a disease that causes hair loss and can carry a significant psychosocial burden. President and Chief
Via MarketBeat · July 13, 2026
Why Micron Is Doubling Down While the HBM Shortage Persistsmarketbeat.com
Micron plans $250 billion in U.S. investment amid a persistent HBM shortage, as analysts maintain a Buy consensus and see substantial upside in the stock's valuation.
Via MarketBeat · July 13, 2026
First Hawaiian to Buy TriCo Bancshares in $2 Billion Stock Deal, Building Pacific Bank Giantmarketbeat.com
First Hawaiian (NASDAQ:FHB) and TriCo Bancshares have entered into a definitive agreement to combine in a 100% stock transaction valued at approximately $2 billion, according to remarks made on an investor call led by executives from both companies. Bob Harrison, chairman, president and chief execu
Via MarketBeat · July 13, 2026
China's Helium Ban Could Reshape the AI Supply Chainmarketbeat.com
China, Russia, and Qatar export curbs have triggered a global helium shortage critical to chip fabrication, pushing prices higher and boosting suppliers like Linde PLC.
Via MarketBeat · July 13, 2026
Analysts See Major Upside for These 5 Stocksmarketbeat.com
NVIDIA, Vistra, Mastercard, Micron, and Energy Transfer carry Buy ratings, high MarketRank scores, and double-digit analyst-implied upside ahead of earnings season.
Via MarketBeat · July 13, 2026
AMD's 5C Deal Positions It as a Direct NVIDIA Rivalmarketbeat.com
AMD's 5C data center partnership positions it as a full-stack AI competitor to NVIDIA, with analysts citing strong price targets, growing coverage, and hypergrowth revenue forecasts ahead.
Via MarketBeat · July 13, 2026
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financingmarketbeat.com
Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer. Founder, Chairman and Chief Executive Off
Via MarketBeat · July 13, 2026
AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains Orbitmarketbeat.com
AST SpaceMobile shares remain volatile amid partnership gains and BlueBird satellite launches, offset by mounting losses, cash burn, and repeated EPS misses that keep Wall Street cautious.
Via MarketBeat · July 13, 2026
3 Dividend Stocks with Growth on Tap for the Second Halfmarketbeat.com
Amid market volatility and geopolitical uncertainty, IBM, Kinder Morgan and Templeton Emerging Markets Fund offer dividend growth and attractive total return potential for investors seeking safety.
Via MarketBeat · July 13, 2026
ME Group International H1 Earnings Call Highlightsmarketbeat.com
ME Group International (LON:MEGP) said it remains on track to meet revised full-year profit expectations after a mixed first half, with growth in its laundry operations offsetting softer photobooth trading and lower equipment sales. Deputy Chief Executive Officer Vladimir Crasneanscki told investor
Via MarketBeat · July 13, 2026
3 Overlooked Stocks Positioned for the Next Market Rotationmarketbeat.com
Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks gaining quiet momentum.
Via MarketBeat · July 13, 2026
3 Non-Tech Stocks Still Winning Big on AImarketbeat.com
Powell Industries, AAON, and EMCOR Group are benefiting from surging data center demand for power, HVAC, and construction services, offering AI-linked growth outside the tech sector.
Via MarketBeat · July 13, 2026
Achieve Robust Diversification With These 3 Equal-Weight ETFsmarketbeat.com
Equal-weight ETFs like RSP, QQEW, and DFVE offer alternatives to market-cap-weighted funds, providing more balanced exposure across holdings with 2026 YTD returns near 12-13%.
Via MarketBeat · July 13, 2026
PageGroup Q2 Earnings Call Highlightsmarketbeat.com
PageGroup (LON:PAGE) reported broadly flat second-quarter gross profit as growth in the Americas and Asia Pacific offset weaker trading in France, Northern Europe and the U.K., with management saying market conditions remain challenging but showing signs of improvement in some regions. Chief Financ
Via MarketBeat · July 13, 2026
MDA Space Bets €567M on CLS to Build AI Geo-Intelligence Platformmarketbeat.com
MDA Space (TSE:MDA) said it has entered into a firm offer to acquire a 70% stake in Collecte Localisation Satellites, known as CLS, in a cash transaction that the company said would expand its Earth observation business into AI-driven data analytics and geo-intelligence services. Chief Executive Of
Via MarketBeat · July 13, 2026
Aritzia Shareholders Back Board as CEO Touts 35% Revenue Growth, U.S. Expansionmarketbeat.com
Aritzia (TSE:ATZ) shareholders approved all formal items at the company’s virtual annual general meeting, including the election of nine directors, the appointment of PricewaterhouseCoopers LLP as auditor and a non-binding advisory resolution on executive compensation. John Currie, Aritzia’s lead d
Via MarketBeat · July 13, 2026
Zapata Quantum Bets Software, AI Partnerships Will Unlock Quantum Computing Valuemarketbeat.com
Zapata Quantum (OTCMKTS:ZPTA) Chief Executive Officer Sumit Kapur used a presentation at the OTC Markets Global Technology Conference to argue that quantum computing is moving from a hardware-focused phase toward one in which software and applications will determine much of the sector’s value. Kapu
Via MarketBeat · July 13, 2026
Contango ORE Drops Gold Hedges to Boost Upside as Manh Choh Output Rampsmarketbeat.com
Contango ORE (NYSEAMERICAN:CTGO) executives said the company has eliminated its remaining gold hedge book by converting the last 15,000 ounces of hedged gold into debt, a move management framed as increasing shareholder exposure to gold prices while preserving equity. Speaking during an investor we
Via MarketBeat · July 12, 2026
Zeta Global Eyes AI Infrastructure Shift as Palantir Integration Nearsmarketbeat.com
Zeta Global (NYSE:ZETA) executives said the company is moving beyond its core marketing technology positioning and toward what they described as an AI infrastructure and business intelligence platform, supported by recently announced partnerships with Palantir, OpenAI and Snowflake. Speaking during
Via MarketBeat · July 12, 2026
Whitestone REIT Shareholders Approve AREG Merger, Reject Executive Pay Planmarketbeat.com
Shareholders of Whitestone REIT (NYSE:WSR) approved the company’s proposed merger with and into AREG Wizard Intermediate LP at a virtual special meeting, according to remarks delivered during the meeting by David Holeman, Whitestone’s Chief Executive Officer and Trustee. The vote clears the shareho
Via MarketBeat · July 12, 2026
Unum Group Cuts Long-Term Care Risk With $3.8B Reinsurance Dealmarketbeat.com
Unum Group (NYSE:UNM) said it has agreed to reinsure an additional portion of its long-term care insurance liabilities, marking the company’s third major external reinsurance transaction and its second involving long-term care. On a conference call with analysts, President and CEO Rick McKenney sai
Via MarketBeat · July 12, 2026
Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Studymarketbeat.com
Teva Pharmaceutical Industries (NYSE:TEVA) said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy
Via MarketBeat · July 12, 2026
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Riskmarketbeat.com
Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety
Via MarketBeat · July 12, 2026
Planet Labs PBC Shareholders Back Directors, KPMG and Pay Plan at Annual Meetingmarketbeat.com
Planet Labs PBC (NYSE:PL) held its 2026 annual meeting of stockholders virtually on July 9, with shareholders voting on three company proposals, according to the meeting transcript. Will Marshall, co-founder, chairperson of the board and chief executive officer of Planet Labs, opened the meeting an
Via MarketBeat · July 12, 2026
MasTec Bets Big on AI Infrastructure With $1.65B Superior Group Dealmarketbeat.com
MasTec (NYSE:MTZ) said it has entered into a definitive agreement to acquire The Superior Group, an electrical infrastructure contractor focused on data centers and other mission-critical markets, in a transaction valued at approximately $1.65 billion upfront. Chief Executive Officer Jose Mas said
Via MarketBeat · July 12, 2026
Element Solutions Lands $14.5B Solstice Deal as AI Data Center Demand Boomsmarketbeat.com
Solstice Advanced Materials said it has agreed to acquire Element Solutions (NYSE:ESI) in a cash-and-stock transaction valued at approximately $14.5 billion, including the assumption of net debt, as the companies outlined plans to create a larger advanced materials platform with a heavier focus on e
Via MarketBeat · July 12, 2026
Equifax Expands in Mexico With $750 Million Círculo de Crédito Dealmarketbeat.com
Equifax (NYSE:EFX) said it has signed a definitive agreement to acquire Círculo de Crédito, which Chief Executive Officer Mark Begor described as the fastest-growing credit bureau in Mexico, for an enterprise value of $750 million. During an investor update call, Begor said the acquisition would ex
Via MarketBeat · July 12, 2026
3 Rare-Earth ETFs That Help Investors Balance Exposure and Riskmarketbeat.com
Federal support for MP Materials, USA Rare Earth, and others is rebuilding U.S. rare-earth refining. REMX, EART, and SETM ETFs offer diversified ways to invest in this supply chain.
Via MarketBeat · July 12, 2026
Dycom Industries Says Fiber, Data Center Demand Gives Backlog ‘Staying Power’dycom
Dycom Industries (NYSE:DY) Chief Executive Officer Dan Peyovich said the company is seeing broad-based demand across fiber, long-haul networks and data center-related services, arguing that the company’s recent backlog growth reflects more than a short-term cyclical upturn. Speaking with Guggenheim
Via MarketBeat · July 12, 2026
Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costsmarketbeat.com
Microsoft is routing some Copilot prompts to its in-house MAI models to cut reliance on OpenAI and Anthropic, aiming to boost margins as MSFT shares trade off 2026 lows.
Via MarketBeat · July 12, 2026
Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbingmarketbeat.com
Delta Air Lines posted strong Q2 2026 results and raised guidance, driven by demand and premiumization, with analysts holding a Moderate Buy rating and price targets up to $110-$116.
Via MarketBeat · July 12, 2026
This Dividend ETF Choice Could Shape Your Income Strategy Through 2026marketbeat.com
VYM and SCHD both offer low-cost dividend exposure, but differ in methodology, yield, and holdings—VYM emphasizes broad, higher-yield diversification, while SCHD focuses on stricter, dividend-growth criteria.
Via MarketBeat · July 12, 2026
Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocksmarketbeat.com
Michael Burry bought DraftKings and Flutter shares, betting regulation will curb prediction markets like Kalshi, as Wall Street analysts also see both sportsbook stocks as undervalued.
Via MarketBeat · July 12, 2026
Capri Charts Post-Versace Comeback With Michael Kors Revamp, Jimmy Choo Growthmarketbeat.com
Capri (NYSE:CPRI) executives said the company is entering a more focused phase after the sale of Versace, with management emphasizing growth plans for Michael Kors and Jimmy Choo, store renovations, tighter product assortments and a stronger balance sheet. Speaking at Bernstein’s Retail Forum in Ne
Via MarketBeat · July 12, 2026
Clarivate to Sell Life Sciences Unit to Altaris for $600M, Refocus Core Businessmarketbeat.com
Clarivate (NYSE:CLVT) said it has reached an agreement to sell substantially all of its Life Sciences & Healthcare segment to Altaris, an investment firm focused on the healthcare industry, in a transaction valued at $600 million. Chief Executive Officer Matti Shem Tov said on a conference call
Via MarketBeat · July 12, 2026
Chewy Annual Meeting: Directors Elected, Deloitte Ratified and Pay Vote Approvedmarketbeat.com
Chewy (NYSE:CHWY) held its 2026 Annual Meeting of Stockholders, with Chairman of the Board Raymond Svider presiding over the virtual meeting and announcing preliminary voting results on four proposals. Svider said the meeting was “duly and lawfully convened” after confirming that notice of the meet
Via MarketBeat · July 11, 2026
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stagemarketbeat.com
Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targets to reflect growth and lessons learned from existing programs. During the company’s 2026 Sustainability Update, Pam Cheng, EVP Global Op
Via MarketBeat · July 11, 2026
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhousemarketbeat.com
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO
Via MarketBeat · July 11, 2026
Veritone Shareholders Back Share Increase, CEO Awards as Debt Questions Loommarketbeat.com
Veritone (NASDAQ:VERI) stockholders approved all six proposals presented at the company’s 2026 Annual Meeting of Stockholders, including the election of two directors, an increase in authorized shares and equity awards for President and Chief Executive Officer Ryan Steelberg. The virtual meeting wa
Via MarketBeat · July 11, 2026
Veritone Maps AI Growth Push as Oracle Partnership Targets Cost Savingsmarketbeat.com
Veritone (NASDAQ:VERI) used a July 7 investor webcast to outline its strategy across artificial intelligence, data management, media, public sector and talent acquisition, with executives emphasizing the company’s focus on unstructured data and AI-enabled workflows. Ryan Steelberg, Veritone’s CEO a
Via MarketBeat · July 11, 2026
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launchmarketbeat.com
Vera Therapeutics (NASDAQ:VERA) said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progression. The company said TRUTAKNA is the first and only BAFF and APRIL inhibitor indicated to redu
Via MarketBeat · July 11, 2026
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readoutmarketbeat.com
Turn Therapeutics (NASDAQ:TTRX) outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by an interim analysis of the first 50 completers in the ongoing trial. Brad Burn
Via MarketBeat · July 11, 2026
TruBridge Stockholders Approve IKS Merger at Special Meetingmarketbeat.com
TruBridge (NASDAQ:TBRG) stockholders approved the company’s proposed merger agreement under which TruBridge will become a subsidiary of Inventurus Knowledge Solutions Inc., or IKS, during a virtual special meeting held July 7, 2026. Glenn Tobin, TruBridge’s Chairman of the Board, opened the meeting
Via MarketBeat · July 11, 2026
Starbucks Builds Sovereign AI to Cut $400 Million in Software Costsmarketbeat.com
Starbucks (SBUX) is building internal AI tools to replace Microsoft and IBM software, targeting $400 million in annual vendor spend and cutting $30 million from its tech budget.
Via MarketBeat · July 11, 2026
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipelinemarketbeat.com
Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market. On an investor call discussin
Via MarketBeat · July 11, 2026
Power Struggle: Wolfspeed Sues Navitas Over AI Chipsmarketbeat.com
Wolfspeed sued Navitas Semiconductor over five wide-bandgap patents, seeking an import injunction and damages, as both companies face debt, cash burn and shifting AI datacenter supply chains.
Via MarketBeat · July 11, 2026
Solstice Advanced Mat Bets on AI Demand With $14.5B Element Solutions Dealmarketbeat.com
Solstice Advanced Mat (NASDAQ:SOLS) announced an agreement to acquire Element Solutions in a cash-and-stock transaction valued at approximately $14.5 billion, including the assumption of net debt, executives said on a conference call discussing the deal. Under the terms outlined by Solstice Preside
Via MarketBeat · July 11, 2026
Why WD-40 Is Proving Great Businesses Never Go Out of Stylemarketbeat.com
WD-40's fiscal Q3 revenue rose 24% and guidance increased, sending shares to a multi-year high. Analysts hold a Buy consensus with a $305 price target, and a new $100 million buyback was authorized.
Via MarketBeat · July 11, 2026
Pushing the Edge: Super Micro Computer Reboots the AI Landscapemarketbeat.com
Super Micro Computer launched a Kubernetes edge AI appliance with Red Hat and Portworx targeting sovereign AI demand, even as shares fell 30% and short interest rose to about 19% of its float.
Via MarketBeat · July 11, 2026
MarketBeat Week in Review – 07/06 - 07/10marketbeat.com
MarketBeat recaps the week's top stories, covering SK Hynix's debut, AI stock rotation, earnings from D.R. Horton, and analysis of Palantir, Microsoft, Meta, Broadcom, Rivian, ASML, and Circle.
Via MarketBeat · July 11, 2026
SBC Medical Group Shareholders Approve Board, Charter Changes at Annual Meetingmarketbeat.com
SBC Medical Group (NASDAQ:SBC) held its 2026 annual meeting of stockholders in a virtual format, with Chairman and Chief Executive Officer Yoshiyuki Aikawa presiding over the meeting. Aikawa said the virtual format was intended to be “more inclusive” and allow the company to reach a greater number
Via MarketBeat · July 11, 2026
Rackspace Technology Cuts 2026 Outlook as $250M Stock Sale Fuels AI Pushmarketbeat.com
Rackspace Technology (NASDAQ:RXT) said it is accelerating its push into enterprise artificial intelligence infrastructure, announcing a $250 million at-the-market equity offering and updated 2026 financial outlook as it moves away from lower-margin revenue streams. On a conference call, Chief Execu
Via MarketBeat · July 10, 2026
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlookmarketbeat.com
RxSight (NASDAQ:RXST) reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustab
Via MarketBeat · July 10, 2026
Ondas Snaps Up DZYNE in $875M Deal, Boosts Autonomous Defense Revenue Targetmarketbeat.com
Ondas (NASDAQ:ONDS) said it has acquired DZYNE Technologies in a transaction valued at approximately $875 million, marking what Chairman and CEO Eric Brock described as a transformational step in building a scaled autonomous defense and security platform. Speaking on an investor event call, Brock s
Via MarketBeat · July 10, 2026
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advancesmarketbeat.com
Ocugen (NASDAQ:OCGN) outlined plans to advance three late-stage retinal disease programs, with company speaker Shankar saying the company is targeting biologics license applications for retinitis pigmentosa and Stargardt disease next year and a third BLA for geographic atrophy in 2028. Speaking dur
Via MarketBeat · July 10, 2026
Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Daymarketbeat.com
Nyxoah (NASDAQ:NYXH) used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability. Chief Executive Officer Olivier Taelman said there is “a lot of excitement in
Via MarketBeat · July 10, 2026
Netskope Shareholders Reelect Directors, Ratify KPMG at Annual Meetingmarketbeat.com
Netskope (NASDAQ:NTSK) held its annual meeting of stockholders virtually on July 7, 2026, with shareholders approving both proposals presented by the company, according to remarks made during the meeting. Sanjay Beri, Netskope’s chairman of the board, chief executive officer and co-founder, called
Via MarketBeat · July 10, 2026
MicroVision Shareholders Clear Reverse Split Plan, Convertible Note Share Issuancemarketbeat.com
Microvision (NASDAQ:MVIS) shareholders approved all five proposals presented at the company’s 2026 annual meeting, including the election of directors, authorization related to convertible notes, and amendments that allow the board to implement a reverse stock split. The virtual meeting was chaired
Via MarketBeat · July 10, 2026
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Updatemarketbeat.com
Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants. The company reported results from four ad
Via MarketBeat · July 10, 2026
Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Studymarketbeat.com
Seres Therapeutics (NASDAQ:MCRB) reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment option for cancer pati
Via MarketBeat · July 10, 2026
Information Services Group Sees AI Cloud Demand Fuel Record Tech Spendingmarketbeat.com
Information Services Group (NASDAQ:III) said technology demand continued to expand sharply in the second quarter, driven primarily by cloud-based software and infrastructure services tied to artificial intelligence, while traditional managed services remained in low-single-digit growth mode. On its
Via MarketBeat · July 10, 2026
Delta Air Lines Q2 Earnings Call Highlightsmarketbeat.com
Delta Air Lines (NYSE:DAL) reported record June-quarter revenue and better-than-expected profitability, with executives telling analysts that strong demand, fare momentum and diversified revenue streams are supporting the carrier’s full-year outlook despite a sharp increase in fuel costs. Chief Exe
Via MarketBeat · July 10, 2026
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Targetmarketbeat.com
AeroVironment shares fell 38% after analyst downgrades on its 2030 targets, yet Q4 revenue hit $642 million with 22% EBITDA margins and a $2.7 billion backlog.
Via MarketBeat · July 10, 2026
Micron's $250 Billion Bet Could Reshape the AI Memory Racemarketbeat.com
Micron accelerated its $250 billion U.S. fabrication buildout, securing a domestic silicon supply deal with GlobalWafers as it races SK Hynix in the HBM4 memory market.
Via MarketBeat · July 10, 2026
Rocket Lab’s Stock Drop Comes With a Bullish Twistmarketbeat.com
Rocket Lab stock is down 45% from its peak, but a record-fast Space Force launch, Morgan Stanley's $293 bull case, and the Iridium deal highlight bullish fundamentals ahead of Aug. 6 earnings.
Via MarketBeat · July 10, 2026
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvementmarketbeat.com
Forte Biosciences (NASDAQ:FBRX) said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued improvement after patients stopped treatment as a key feature of the results. On a company data call,
Via MarketBeat · July 10, 2026
MTY Food Group Q2 Earnings Call Highlightsmarketbeat.com
MTY Food Group (TSE:MTY) reported lower second-quarter earnings as softer consumer traffic, inflation in key food categories and weaker corporate-store performance weighed on results, while management outlined plans to close 68 underperforming corporate-owned restaurants following a detailed portfol
Via MarketBeat · July 10, 2026
Amazon’s New Debt Deal Puts Its AI Spending Story on Trialmarketbeat.com
Amazon sold $25 billion in bonds to fund a $200 billion 2026 AI infrastructure push, even as weaker bond demand and rising insider stock sales signal investor caution.
Via MarketBeat · July 10, 2026
Broadcom's $30 Billion Apple Deal: This Chip Giant Is About More than Just AIbroadcom
Broadcom extended its chip supply deal with Apple through 2031, valued at over $30 billion, highlighting its non-AI semiconductor and infrastructure software revenue beyond its core AI chip business.
Via MarketBeat · July 10, 2026
Articles from MarketBeat | FWNBC